joint venture

The two firms will provide €14M ($16.2 million) of equity funding to commercialize the Idylla platform in the Chinese market.

The planned joint venture with Beijing Zishan Health Consultancy is aimed at bringing Genetic Technologies' genomic tests to the Chinese market.

A new company will be established to develop a service platform using blockchain technology for medical services and personalized health management.

The partners plan to apply genomics to traditional Chinese medicine.

The companies formed the joint venture in 2008 to commercialize BioMérieux's IVD products and medical instruments in Japan.

The new company will develop microbiome diagnostics for multiple indications including inflammatory bowel disease and liver disorders.

Fulgent reached an agreement with two Chinese firms to establish a joint venture to offer genetic testing services in China. 

The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.

Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.